Definition of the viral targets of protective HIV-1-specific T cell responses
about
HIV-Host Interactions: Implications for Vaccine DesignCan immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Fitness costs of mutations at the HIV-1 capsid hexamerization interfaceResistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccineCoupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated ImmunityEpigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus VaccineLatency reversal and viral clearance to cure HIV-1.Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.HIV subtype influences HLA-B*07:02-associated HIV disease outcome.Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccinesA correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllersLow-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controllerAutologous HIV-1 clade-B Nef peptides elicit increased frequency, breadth and function of CD8+ T-cells compared to consensus peptides.Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesPathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.Plant-based vaccines against viruses.Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine designHIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominanceVaccines that stimulate T cell immunity to HIV-1: the next stepIdentification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.A restriction enzyme based cloning method to assess the in vitro replication capacity of HIV-1 subtype C Gag-MJ4 chimeric viruses.Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.CD8+ TCR Bias and Immunodominance in HIV-1 Infection.Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen TypesHIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaquesAviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell ResponsesHIV control through a single nucleotide on the HLA-B locus.Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.
P2860
Q26765966-2923CDEF-B6CB-47E5-A6FB-53A89802D534Q26865388-3355CE5B-5EED-4392-B486-CAA151DFFE24Q28533915-EF4A7EC1-FF8C-4412-9EBC-D9AFE312B0E7Q28534573-79C46E8C-FF3F-41E4-ADC3-C855AAB476C3Q28603015-18C0E270-FDE7-4042-89E7-53D5FC886618Q28822525-D4E9E10B-5EAB-40AA-9915-38AD24B97124Q30248766-F2054C46-8DFE-4AE6-BA03-11B7D244A1DEQ30381239-405E17C6-E30C-474C-9A9F-48A3B6224E41Q30934059-D63CE80A-84DA-455C-BCC3-F3158401F6BEQ33566546-79F4E20D-292E-49C7-996E-5E652D5D004CQ33610621-58E165D3-B2D2-454E-8BE0-E0A70C232FCBQ33982102-9BD6B013-C284-415E-A550-E993565EA7D2Q34182086-2E6C7886-76E5-4196-9713-52B9497D55C8Q34490157-59DDF2F0-0A92-41E3-928D-E9374A6454E5Q34499377-112783B0-66A4-4037-9104-D1E165BF9704Q34594538-616C9B6E-02E3-4656-99AA-F948B46C651BQ34594624-253D953C-3C43-484C-A54A-643C5BD96456Q34616275-0612E85C-76B7-4E65-96C4-C1CCC3DAE867Q34650866-05CD2B00-C88B-41E4-9790-58D0697F86BBQ34653619-4CEF2134-E887-4EC9-8D2D-6581E904140EQ34664829-3AA2BD74-B9F5-4989-8439-BB39A40D9418Q34687464-96AF9963-2EE2-4A4E-B15B-F9D94FB8CF49Q34760497-1141E26F-EBD8-4C0E-884C-10AA3C832E67Q34789269-3949D780-CFE9-4412-99D9-1C7ED61B6537Q34874985-0CCB88FE-CE0C-4766-9EEA-F3512813C25DQ34984237-7E3F9CFE-4314-459D-A441-2A9B03BBFB4BQ34991038-02438E82-5013-4670-9368-81F34B92CFF1Q35073079-EC57E65C-59EB-420D-AB68-FA14F15C2F60Q35130519-1C819CA2-F398-4BF6-AB86-4C33633663BBQ35190453-2ACBFE6D-5813-488A-AD29-C51AD4E0C355Q35194792-CD0F07A1-0243-4FB7-985A-4D80BACA6B14Q35613273-965FFEFE-C002-4355-88EB-D7C0584A8064Q35641386-C9803F73-34ED-4C8A-AA6C-598FD5BCA430Q35797743-6949B695-4D66-41B7-AEAD-7717902B52BDQ35973632-7575A3FF-8D58-484F-B28A-496B8CBA1802Q36086711-6EC63E65-0523-4E71-8BB8-199E0A8175B8Q36256319-A18053E8-96D9-4004-A873-ECE2721C96F4Q36319368-22A4B5ED-119A-4177-9B99-3657E0F1F10BQ36363448-3293E73D-4383-44B1-97BE-013ACB47F42CQ36397593-6220CF28-42EC-4287-9CC4-270FCED7BDC7
P2860
Definition of the viral targets of protective HIV-1-specific T cell responses
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Definition of the viral targets of protective HIV-1-specific T cell responses
@ast
Definition of the viral targets of protective HIV-1-specific T cell responses
@en
type
label
Definition of the viral targets of protective HIV-1-specific T cell responses
@ast
Definition of the viral targets of protective HIV-1-specific T cell responses
@en
prefLabel
Definition of the viral targets of protective HIV-1-specific T cell responses
@ast
Definition of the viral targets of protective HIV-1-specific T cell responses
@en
P2093
P2860
P50
P356
P1476
Definition of the viral targets of protective HIV-1-specific T cell responses
@en
P2093
Anuska Llano
Cristina Miranda
James I Mullins
James J Szinger
Javier Ibarrondo
Jennifer Zamarreño
Jorge Sanchez
Jose M Gatell
Marcus Daniels
Marilu Farfan
P2860
P2888
P356
10.1186/1479-5876-9-208
P50
P577
2011-12-07T00:00:00Z
P5875
P6179
1029954299